Study Cites Pfizer Inc. Smoking Drug Risk, Shares Fall

WASHINGTON (Reuters) - Hundreds of patients taking Pfizer Inc's anti-smoking drug Chantix have reported serious accidents, vision problems and heart trouble, researchers said on Wednesday, sending shares of the world's largest drugmaker to their lowest level since 1997.
MORE ON THIS TOPIC